Reovirus-therapy triggers cancer self destruction


Leeds/Calgary – Oncolytic reoviruses not only kill cancer cells directly but also force them to secrete cytokines that recruit cancer killing cells from the innate and adaptive immune system. According to researchers from Leeds University (UK) and the Canadian biotech firm Oncolytics Biotech, which is conducting several Phase II study with its reovirus-based cancer treatment Reolysin, this opens up the potential of cancer treatment by "bystander" immune-mediated therapy even in the absence of live virus. Published in Molecular Cancer, researchers showed that growth media from reovirus-infected melanoma cells contained pro-inflammatory cytokins such as IL-8 and Interferon beta (INF-beta), which recruited and activated white blood cells, specifically Natural Killer (NK) cells, dendritic cells (DC) and anti melanoma cytotoxic T cells (CTL) which killed off the tumour. The effect was dependent on inactivation of the protein PKR, which protects non-cancer cells from reovirus infection, and the presence of NF-kappaB. The study shows that reovirus therapy can be effective even though reovirus is cleared shortly after infection, through immune system induction of a tumour-specific immune response that initiates apoptosis of tumour cells.



London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...



Surrey – The UK government is investing an additional £80m (€93.5m) to fund continued development of the Institute for Animal Health (IAH) at Pirbright, an institute of the Biotechnology and Biological Sciences Research Council...



Rijeka/London – Allergies like asthma or psoriasis might arise from environmental toxins, suggest researchers from Rijeka University (Croatia) and King’s College (London). In mice, they identified a special population of T cells...



London – Interesting times ahead in the European cancer treatment market. A report states that in the UK alone, diagnosis and treatment costs are likely to increase by 62%, from £9.4 billion in 2010 to £15.3 billion by 2021. The...



York - Tissue Regenix Group plc plans to raise €29m through the sale of 181.8 million shares. The regenerative medical device company is held within the IP Group portfolio and a spin-out company from the University of Leeds. The...



London – Cancer Research UK has begun recruiting patients in the first phase of its Stratified Medicine Programme, which is aimed at finding cancer biomarkers and establishing a genetic testing service in the UK. The charity’s...



London – British Prime Minister David Cameron is trying to come to the rescue of Britain’s embattled biopharmaceutical industry. He has earmarked €210m to support a “biomedical catalyst fund” to back early-stage academic and...



London - David Cameron plans to come to the rescue of Britain's embattled biopharmaceutical industry. The conservative prime minister has earmarked £180m (€210 million) to support a "biomedical catalyst fund" to back ...



Cancer Research UK has started recruiting patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The charity's multi-million...

Displaying results 11 to 20 out of 396

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues